Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study

Liang Jen Wang, Ching Shu Tsai, Wen Jiun Chou, Chia Jung Li, Sheng Yu Lee, Yi Chun Chen, I. Chun Lin*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

Abstract

Introduction: The BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disorders (ND) (e.g., attention-deficit/hyperactivity disorder [ADHD], autism spectrum disorder [ASD], communication disorders, intellectual disability, and tic disorders) and healthy control children. Methods: A total of 1335 children who received the SARS-CoV-2 vaccination (762 children with ND and 573 healthy controls) were recruited. All subjects were followed-up for 180 days, and outcome events were defined as outpatient department (OPD) or emergency department (ER) visits during follow-up. Multivariate Cox proportional hazards regression models were used to identify the potential differences in outcomes between the propensity score-matched ND group (n = 311) and the control group (n = 311), and to explore the factors associated with outcomes among all children with ND (n = 762). Results: Compared with the control group, children with ND exhibited a higher likelihood of subsequent OPD or ER visits and paediatric neurology OPD visits after the first dose of vaccination. However, we found that only a small proportion of the children visited the OPD or ER because of adverse vaccination-related effects. Among all children with ND, those with communication disorders showed a higher likelihood of any OPD or ER visit. Paediatric neurology OPD visits were associated with communication disorders, intellectual disability, and methylphenidate and aripiprazole prescriptions. ADHD and ASD were not associated with adverse outcomes. Conclusions: No specific ND diagnosis or medication use clearly increased the risk of adverse effects of SARS-CoV-2 vaccination. Children with ND can be reassured that the SARS-CoV-2 vaccination is a safe regimen to protect themselves.

Original languageEnglish
Pages (from-to)4267-4273
Number of pages7
JournalVaccine
Volume41
Issue number29
DOIs
StatePublished - 29 06 2023

Bibliographical note

Copyright © 2023 Elsevier Ltd. All rights reserved.

Keywords

  • Children
  • Neurodevelopmental disorder
  • SARS-CoV-2
  • Safety
  • Vaccine
  • Vaccination/adverse effects
  • Follow-Up Studies
  • Humans
  • Autism Spectrum Disorder
  • BNT162 Vaccine
  • Neurodevelopmental Disorders/chemically induced
  • Drug-Related Side Effects and Adverse Reactions
  • Adolescent
  • COVID-19/prevention & control
  • COVID-19 Vaccines/adverse effects
  • Child
  • Intellectual Disability
  • Longitudinal Studies

Fingerprint

Dive into the research topics of 'Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study'. Together they form a unique fingerprint.

Cite this